Grant ID RP200464
Awarded On August 19, 2020
Title Arming an Oncolytic Herpes Simplex Virus to "BiTE" Tumor Cells
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization University of Houston
Principal Investigator/Program Director Xiaoliu Zhang
Cancer Sites All Sites
Contracted Amount $702,581*

*Pending contract negotiation

Lay Summary

US Food and Drug Administration (FDA) has recently approved a type I herpes simplex virus (HSV-1) based oncolytic virus, T-VEC (Imlygic), for treatment of melanoma. This is the first FDA approval for virotherapy, a new type of cancer treatment that is based a pragmatic therapeutic principle - purposefully modifying a virus so that it can selectively kill malignant cells. My laboratory has employed a novel mechanism to create a HSV-2-based oncolytic virus, the first of this kind (all other oncolytic HSVs, including, T-VEC are constructed from HSV-1). Designated FusOn-H2, it showed potent activity against many tumor types, including breast cancer, pancreatic cancer, ovarian cancer and prostate...

Read More